CHCWM – Cancer & Hematology Centers of West Michigan

AstraZeneca D910DC00001 (EMERALD2)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Principal Investigator: Dr. Manish Sharma

For more information on this trial, read its profile on clinicaltrials.gov here.